Search and analyze individual stocks with comprehensive metrics
Aarti Pharmalabs Limited
Fundamental Score
Aarti Pharmalabs Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of AARTIPHARM across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Excellent ROCE Performance (17.44%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Conservative Debt Levels (D/E: 0.21)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (13.22x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Risk Factors
3 factors identified
Profit Decline Concern (-10.73%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-30.48%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Negative Free Cash Flow (₹-149.15 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Aarti Pharmalabs Limited
About AARTIPHARM
Company Details
Market Information
Performance
AARTIPHARM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of AARTIPHARM?
AARTIPHARM is currently trading at ₹824.85 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of AARTIPHARM shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of AARTIPHARM and what does it mean?
AARTIPHARM has a P/E ratio of 29.15x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹29 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is AARTIPHARM performing according to Bull Run's analysis?
AARTIPHARM has a Bull Run fundamental score of 28.7/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 14.54%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does AARTIPHARM belong to?
AARTIPHARM operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Aarti Pharmalabs Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for AARTIPHARM?
AARTIPHARM has an ROE of 14.54%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Aarti Pharmalabs Limited generates profits from shareholders' equity. An ROE of 15% means the company generates ₹15 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is AARTIPHARM's debt-to-equity ratio and what does it indicate?
AARTIPHARM has a debt-to-equity ratio of 0.21, which indicates conservative financing with low financial risk. This means the company has ₹21 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is AARTIPHARM's dividend yield and is it a good dividend stock?
AARTIPHARM offers a dividend yield of 0.58%, which means you receive ₹0.58 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has AARTIPHARM grown over the past 5 years?
AARTIPHARM has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in AARTIPHARM and why does it matter?
Promoters hold 43.72% of AARTIPHARM shares, with 0.01% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: -0.57%.
How does AARTIPHARM compare with its industry peers?
AARTIPHARM trades at P/E 29.15x vs industry average 33.97x, with ROE of 14.54% and ROCE of 17.44%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether AARTIPHARM is outperforming its competitive set in profitability, growth, and valuation metrics.
What is AARTIPHARM's market capitalization and what category does it fall into?
AARTIPHARM has a market capitalization of ₹7767 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for AARTIPHARM?
Key ratios for AARTIPHARM: ROE 14.54% (Good), ROCE 17.44%, P/E 29.15x, Debt-to-Equity 0.21, Interest Coverage 13.22x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is AARTIPHARM stock and what is its beta?
AARTIPHARM has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for AARTIPHARM?
AARTIPHARM has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹824.85, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in AARTIPHARM?
Key risks for AARTIPHARM include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.21), and operational challenges. The stock has a Fundamental Score of 28.7/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is AARTIPHARM's operating profit margin and how has it trended?
AARTIPHARM has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is AARTIPHARM's quarterly performance in terms of sales and profit growth?
AARTIPHARM's recent quarterly performance shows YoY Sales Growth of -30.48% and YoY Profit Growth of -10.73%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in AARTIPHARM?
AARTIPHARM has FII holding of 7.34% and DII holding of 7.80%, totaling 15.14% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.